Acrux Limited · ASX:ACR
Acrux — Investor Presentation (February 2024)
11 slides from Acrux's investor presentation, Feb 27, 2024
Slide 1: ACRUX Ltd Investor Presentation February 2024
ACRUX Ltd Investor Presentation February 2024 Acrux is a specialty pharmaceutical company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. 1
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers This presentation contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of p
Slide 3: 2023 Key Milestones
2023 Key Milestones Reported progress towards strategic objective of building a sustainable revenue stream capable of funding development pipeline: Approved • Dapsone 5%, Gel a generic of topical acne treatment Aczone®, approved by the FDA in June 2023 Accepted for review • Nitroglycerin 0.4%, Ointm
Slide 4: Acrux portfolio
Acrux portfolio The Company now has: • 15 products in its portfolio • 6 approved products of which 2 are currently revenue generating, 1 product that will soon be launched and 2 products that formerly generated revenue for Acrux • 3 products currently being reviewed by the FDA Progression of Acrux’s
Slide 5: Product portfolio
Product portfolio1 Prilocaine / Lidocaine Cream Evamist® Dapsone 5%, Gel Efinaconazole Topical Solution Testosterone Topical Solution Lenzetto® Dapsone 7.5%, Gel Acyclovir Cream Nitroglycerine Ointment undisclosed Bioequivalence Development Development Formulation Submission Regulatory generating Ap
Slide 6: Acrux is focussed on an underserved market segment
Acrux is focussed on an underserved market segment Source: 1. US market by dosage form, IQVIA Q3, 2020 MAT, US$ market sales 6 2. Market size for topically applied drugs IQVIA Q3, 2020 MAT, USS market sales
Slide 7: Key Objectives FY24
Key Objectives FY24 Launch Dapsone 5%, Gel Revenue growth from new products, including Prilocaine 2.5% and Lidocaine 2.5%, Cream and Dapsone 5%, Gel Obtain FDA approval and launch products currently under FDA review Advance additional pipeline products 7
Slide 8: Total Revenue
Total Revenue • Total Revenue increased to $5.77 million for the 6 months ended 31 December 2023, an increase of $2.528 million on the prior corresponding period • As pipeline products are approved and launched Acrux’s continuing licensing Revenue is expected to grow: • Prilocaine 2.5% and Lidocaine
Slide 9: Profitability and Cash Generation
Profitability and Cash Generation Profit / (Loss) after Tax $'000 HYE 12/21 HYE 12/22 HYE 12/23 Total Revenue 2,097 3,249 5,777 Less COGS 0 493 3,928 Less Operating Expenses External R&D 3,314 1,926 1,147 Employee and NED Benefits 2,971 2,934 2,780 Other Expenses 1,123 979 784 7,407 5,840 4,711 Prof
Slide 10: Acrux investment opportunity
Acrux investment opportunity Track record of developing and commercialising products to deliver growing recurring revenue streams Strong pipeline of products under development 3 products currently under evaluation by the FDA Received FDA approval of 4 products since 2021 Lidocaine 2.5% and Prilocain
Slide 11: Connecting with Acrux
Connecting with Acrux www.acrux.com.au ASX: ACR info@acrux.com.au +61 3 8379 0100 Follow us on LinkedIn 03 8379 0100 11